Comparative proteomic analysis of vancomycin-sensitive and vancomycin-intermediate resistant Staphylococcus aureus
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: The extensive use of vancomycin has led to the development of Staphylococcus aureus strains with varying degrees of resistance to vancomycin. The present study aimed to explore the molecular causes of vancomycin resistance by conducting a proteomics analysis of subcellular fractions isolated from vancomycin-intermediate resistant S. aureus (VISA) and vancomycin-sensitive S. aureus (VSSA) strains.
METHODS: We conducted proteomics analysis of subcellular fractions isolated from 2 isogenic S. aureus strains: strain 11 (VSSA) and strain 11Y (VISA). We used an integrated quantitative proteomics approach assisted by bioinformatics analysis, and comprehensively investigated the proteome profile. Intensive bioinformatics analysis, including protein annotation, functional classification, functional enrichment, and functional enrichment-based cluster analysis, was used to annotate quantifiable targets.
RESULTS: We identified 128 upregulated proteins and 21 downregulated proteins in strain 11Y as compared to strain 11. The largest group of differentially expressed proteins was composed of enzymatic proteins associated with metabolic and catalytic activity, which accounted for 32.1% and 50% of the total proteins, respectively. Some proteins were indispensable parts of the regulatory networks of S. aureus that were altered with vancomycin treatment, and these proteins were related to cell wall metabolism, cell adhesion, proteolysis, and pressure response.
CONCLUSION: Our proteomics study revealed regulatory proteins associated with vancomycin resistance in S. aureus. Some of these proteins were involved in the regulation of cell metabolism and function, which provides potential targets for the development of strategies to manage vancomycin resistance in S. aureus.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 43(2024), 1 vom: 21. Jan., Seite 139-153 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Jian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6Q205EH1VU |
|---|
| Anmerkungen: |
Date Completed 09.01.2024 Date Revised 09.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10096-023-04709-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364769424 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364769424 | ||
| 003 | DE-627 | ||
| 005 | 20240114233024.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10096-023-04709-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1253.xml |
| 035 | |a (DE-627)NLM364769424 | ||
| 035 | |a (NLM)37985551 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hu, Jian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative proteomic analysis of vancomycin-sensitive and vancomycin-intermediate resistant Staphylococcus aureus |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.01.2024 | ||
| 500 | |a Date Revised 09.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a PURPOSE: The extensive use of vancomycin has led to the development of Staphylococcus aureus strains with varying degrees of resistance to vancomycin. The present study aimed to explore the molecular causes of vancomycin resistance by conducting a proteomics analysis of subcellular fractions isolated from vancomycin-intermediate resistant S. aureus (VISA) and vancomycin-sensitive S. aureus (VSSA) strains | ||
| 520 | |a METHODS: We conducted proteomics analysis of subcellular fractions isolated from 2 isogenic S. aureus strains: strain 11 (VSSA) and strain 11Y (VISA). We used an integrated quantitative proteomics approach assisted by bioinformatics analysis, and comprehensively investigated the proteome profile. Intensive bioinformatics analysis, including protein annotation, functional classification, functional enrichment, and functional enrichment-based cluster analysis, was used to annotate quantifiable targets | ||
| 520 | |a RESULTS: We identified 128 upregulated proteins and 21 downregulated proteins in strain 11Y as compared to strain 11. The largest group of differentially expressed proteins was composed of enzymatic proteins associated with metabolic and catalytic activity, which accounted for 32.1% and 50% of the total proteins, respectively. Some proteins were indispensable parts of the regulatory networks of S. aureus that were altered with vancomycin treatment, and these proteins were related to cell wall metabolism, cell adhesion, proteolysis, and pressure response | ||
| 520 | |a CONCLUSION: Our proteomics study revealed regulatory proteins associated with vancomycin resistance in S. aureus. Some of these proteins were involved in the regulation of cell metabolism and function, which provides potential targets for the development of strategies to manage vancomycin resistance in S. aureus | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Large-quantity proteomics | |
| 650 | 4 | |a S. aureus | |
| 650 | 4 | |a VISA | |
| 650 | 4 | |a Vancomycin resistance | |
| 650 | 4 | |a hVISA | |
| 650 | 7 | |a Vancomycin |2 NLM | |
| 650 | 7 | |a 6Q205EH1VU |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Han, Xinjun |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiaoxue |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xutao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Zhenping |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Peilan |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Zhao |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Yongzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Peiru |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Long |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yali |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Wenhui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology |d 1988 |g 43(2024), 1 vom: 21. Jan., Seite 139-153 |w (DE-627)NLM012620742 |x 1435-4373 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2024 |g number:1 |g day:21 |g month:01 |g pages:139-153 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10096-023-04709-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2024 |e 1 |b 21 |c 01 |h 139-153 | ||